NASDAQ
23.12.24
19:35 Uhr
4,110 US-Dollar
+0,165
+4,18 %
+4,18 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts | 3 | MarketBeat | ||
| Mi | C4 Therapeutics stock hits 52-week low at $3.77 | 4 | Investing.com | ||
| Mi | C4 Therapeutics-Aktie erreicht 52-Wochen-Tief bei 3,77 US-Dollar | 2 | Investing.com Deutsch | ||
| 09.12. | Aktien von C4 Therapeutics steigen nach positiven frühen Krebsstudienergebnissen | 6 | Investing.com Deutsch | ||
| 09.12. | C4 Therapeutics stock surges on positive early cancer trial results | 2 | Investing.com | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.12. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader | 86 | GlobeNewswire (Europe) | In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR)... ► Artikel lesen | |
| 20.11. | C4 Therapeutics beruft Steve Hoerter in den Vorstand | 2 | Investing.com Deutsch | ||
| 20.11. | C4 Therapeutics appoints Steve Hoerter to board | 1 | Investing.com | ||
| 20.11. | C4 Therapeutics, Inc.: C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 20.11. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.10. | C4 Therapeutics GAAP EPS of -$0.35 beats by $0.05, revenue of $15.36M beats by $10.76M | 4 | Seeking Alpha | ||
| 31.10. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 31.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 95 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 26.10. | C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update | 2 | MarketBeat | ||
| 15.10. | C4 Therapeutics appoints Paige Mahaney as new CSO | 3 | Investing.com | ||
| 15.10. | C4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. | 118 | GlobeNewswire (Europe) | Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific... ► Artikel lesen | |
| 14.10. | C4 Therapeutics ändert Anreizplan und verbietet Neubewertung ohne Zustimmung der Aktionäre | 3 | Investing.com Deutsch | ||
| 14.10. | C4 Therapeutics amends incentive plan, barring repricing without shareholder nod | 2 | Investing.com |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,120 | +0,90 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,409 | +12,05 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,000 | -7,22 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,595 | +9,28 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,810 | -0,66 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,140 | +4,13 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,860 | -3,50 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,660 | +1,49 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | 0,00 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,360 | +0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,950 | +3,75 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,610 | +4,00 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,190 | -5,56 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
Das Unternehmen C4 THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,110 Euro und damit +4,18 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.
